Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- (-) Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- (-) Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- (-) Value-Based Contracts
- (-) Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- (-) Value Assessment Methods
Resource Type
Resource Type
Audience
Display Only
Showing 21 Results
How Reforms Can Enable Payment Innovation That Drives Value
This NPC study models the effects of recent and proposed payment reforms related to CMS' best price reporting rules and sheds light on which approaches may encourage the adoption of value-based…
Kimberly Westrich Talks Benefit Design with AJMC
NPC's Vice President of Health Services Research, Kimberly Westrich, MA, discusses how the healthcare system can incentivize high-value care.
Racial and Socioeconomic Disparities: Ignoring Inequitable Benefit Design Is Not an Option
In a new commentary published in BenefitsPro, Kimberly Westrich, NPC Vice President for Health Services Research, and Bruce Sherman, MD, medical advisor for the National Alliance of Healthcare…
Empowering the Patient Voice in Value Assessment: Paving the Way for MCDA
The National Health Council (NHC) and National Pharmaceutical Council (NPC) co-hosted a webinar that explored how multi-criteria decision-making analysis (MCDA) can be used in value assessment.
NPC Patient-Reported Measures Research Featured at AMCP Nexus 2020
A panel at the Academy of Managed Care Pharmacy Nexus 2020 explored the tension between patient-reported measures funding and innovation and highlighted published research by NPC and Discern Health.
Multi-Criteria Decision Analysis: A Way to Put Patient Concerns Front and Center in Value Assessment?
NHC and NPC released a white paper outlining multi-criteria decision analysis (MCDA), an approach to value assessment that may more holistically address patients’ concerns, experiences and treatment…
How Can Payers Advance Patient-reported Measures in Oncology, and Why Should We Care?
A peer-reviewed study describes the current state of patient-reported measures and patient-reported performance measures in oncology, the barriers to implementation, and actionable recommendations…
Supporting Value-Based Purchasing Through Changes in Medicaid Best Price
In a recent column for PharmaBoardroom, Michael Ciarametaro, vice president for research at the National Pharmaceutical Council, elaborated on the ways in which MBP presents a barrier to creative…
NPC Comments on CMS Best Price and Barriers to Value-Based Arrangements
NPC outlines how Medicaid Best Price poses a barrier to implementing value-based arrangements and hinders innovation in payment and delivery systems, which can make it difficult for patients to…
Ready, Fire, Aim: How Not to Approach COVID Pricing Discussions
NPC raises concerns about various approaches to considering pricing for COVID-19 treatments.
Are Value-based Arrangements the Answer We’ve Been Waiting For?
A study by NPC suggests that while value-based arrangements can be one of many tools that payers leverage to address rising costs, it is also important to recognize the strengths and limitations…
Paying for Cures: Ensuring Patient Access and System Sustainability
One of the most vexing challenges facing the U.S. health care system is how payers and biopharmaceutical innovators can work together to ensure that curative treatments are more broadly accessible to…
Value-Based Agreements May Be More Prevalent Than Assumed
As the US health care system continues to transition from volume to value, NPC/Duke-Margolis research shows that value-based agreements between payers and biopharmaceutical manufacturers may be more…
NPC in Specialty Pharmacy Times: Health Care Economic Information and Its Impact on Value-Based Contracts
In his latest column in Specialty Pharmacy Times, NPC President and Chief Executive Officer Dan Leonard explains how expanding HCEI for sophisticated audiences like payers and population health…
NPC in Chain Drug Review: Pharmacy Outlook 2018
NPC President Dan Leonard explores value- and outcomes-based contracts, innovative benefit design, value assessment frameworks and more in his latest commentary for Chain Drug Review.
Opportunities and Challenges With Value-Based Contracting
In his commentary for the American Journal of Pharmacy Benefits, NPC President Dan Leonard explores the challenges and opportunities in implementing value-based contracts.
Learn More About Oncology Clinical Pathways in Webinar from Turning the Tide Against Cancer
Ideally, clinical pathways can be a useful tool to help clinicians make sense of quickly evolving science, ensure patients receive the right care at the right time, help standardize care and limit…